Zydus Lifesciences Limited and Torrent Pharmaceuticals Limited announced that they have entered into a licensing and supply agreement to co-market, Saroglitazar Mg for the treatment of Non-Alcoholic Steato Hepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) in India. Nearly 25-30 % of the adult population in India is estimated to be suffering from NAFLD1. Of this, almost 59.10% are estimated to be suffering from NASH2.

A progressive disease of the liver NAFLD starts with fat accumulation in the liver in patients who do not consume alcohol or take it in insignificant amounts, but have risk factors such as overweight or obesity, diabetes mellitus (high blood sugar), hypertension (high blood pressure) or dyslipidemia (abnormal blood lipids). Saroglitazar Mg is uniquely poised with its dual PPAR alpha and gamma properties. In March 2020, Saroglitazar M g received approval for the treatment of NASH.

Later that year, the drug was also approved for the treatment of NAFLD. It now offers a safe and efficacious way to treat NASH and NAFLD. Zydus continues to market the drug under brand names Lipaglyn®?

and Bilypsa®?. The novel drug was launched in India in September 2013, for the treatment of diabetic dyslipidemia and hypertriglyceridemia in patients with type-2 diabetes not controlled by statins alone. Since then, over 15 lac patients have benefitted from this drug.

It reduces comorbidities (dyslipidemia, hypertriglyceridemia, and diabetes mellitus). In January 2020, SaroglitazarMg was approved for treating Type 2 Diabetes Mellitus.